Read by QxMD icon Read

Thrombosis Research

Adi Tabib, Issam Hindi, Netanel Karbian, Orly Zelig, Batla Falach, Dror Mevorach
BACKGROUND: Thrombosis is the prognostic factor with the greatest effect on survival in patients with paroxysmal nocturnal hemoglobinuria (PNH), who lack dozens of membrane surface proteins. We recently described a primary homozygous Cys89Tyr congenital nonfunctioning CD59 in humans with clinical manifestation in infancy, associated with chronic hemolysis, recurrent strokes, and relapsing peripheral demyelinating neuropathy. Here we investigated hypercoagulability mechanisms characterizing the syndrome...
June 11, 2018: Thrombosis Research
Hiroyuki Kuma, Ryo Matsuda, Asuna Nakashima, Kazuna Motoyama, Shinya Takazaki, Hinako Hatae, Xiuri Jin, Tomohide Tsuda, Hiroko Tsuda, Naotaka Hamasaki
No abstract text is available yet for this article.
June 9, 2018: Thrombosis Research
R Marlu, P Malvezzi, L Seyve, T Jouve, J Maurizi, F Defendi, P L Carron, M Christophe, A Le Gouellec, B Polack, L Rostaing
No abstract text is available yet for this article.
June 7, 2018: Thrombosis Research
Juergen Koessler, Valerie-Noelle Trulley, Andrea Bosch, Katja Weber, Angela Koessler, Markus Boeck, Anna Kobsar
INTRODUCTION: Adenosine diphosphate (ADP) as physiological activator of human platelets mediates its effects via three purinergic receptors: P2Y1, P2Y12 and P2X1. The inhibition of P2Y12 is used pharmacologically to suppress aggregation underlining the physiological significance of this receptor. Since the regulation of purinergic receptor expression has not thoroughly been investigated yet, this study analyzed the content of purinergic receptors on the platelet surface membrane upon activation and inhibition...
June 5, 2018: Thrombosis Research
Frederik Nanne Croles, René Mulder, André B Mulder, Michaël V Lukens, Karina Meijer
Hereditary antithrombin deficiency is associated with a high incidence of venous thromboembolism (VTE), but VTE risk differs between families. Beta-antithrombin is reported to be the most active isoform of antithrombin in vivo. Whether β-antithrombin activity and subtypes in antithrombin deficiency have impact on VTE risk has not been investigated outside the proband setting. We performed a retrospective family cohort study to investigate whether subtypes of antithrombin deficiency or β-antithrombin levels are associated with the risk of first or recurrent VTE...
June 2, 2018: Thrombosis Research
Xingbo Mo, Huan Zhang, Shufeng Lei, Tan Xu, Aili Wang, Zhirong Guo, Yonghong Zhang
No abstract text is available yet for this article.
June 2, 2018: Thrombosis Research
Bengt Zöller
No abstract text is available yet for this article.
June 2, 2018: Thrombosis Research
Aurélien Delluc, Mark Clemons
No abstract text is available yet for this article.
June 2, 2018: Thrombosis Research
Lu-Chen Weng, Weihua Guan, Lyn M Steffen, James S Pankow, Nathan Pankratz, Ming-Huei Chen, Mary Cushman, Saonli Basu, Aaron R Folsom, Weihong Tang
INTRODUCTION: Data from epidemiological studies and clinical trials suggest an influence of dietary and circulating polyunsaturated fatty acids (PUFAs) on the hemostasis profile. Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) related to plasma PUFAs levels. We aimed to investigate whether the SNPs related to plasma PUFAs levels were also associated with plasma levels of hemostatic variables. MATERIALS AND METHODS: We tested the associations between 9 PUFA-related SNPs and 6 hemostatic variables in 9035 European Americans (EAs) and 2702 African Americans (AAs) in the Atherosclerosis Risk in Communities (ARIC) Study...
June 1, 2018: Thrombosis Research
Walid Saliba, Amir Warwar, Antonio Kotler, Shai Cohen, Nili Stein, Gad Rennert, Deborah L Ornstein, Meir Preis
INTRODUCTION: Factor V (FV) deficiency is a rare inherited coagulation disorder associated with bleeding tendency. As a result, it has been postulated that decreased FV activity may confer protection against venous thromboembolism and atherothrombotic cardiovascular events. MATERIALS AND METHODS: Using the electronic database of the largest health care provider in Israel, we identified all adult individuals who were tested for FV activity between January 2004 and June 2017...
May 31, 2018: Thrombosis Research
Craig I Coleman, W Frank Peacock, Thomas J Bunz, Jan Beyer-Westendorf
BACKGROUND: In phase III trials, rivaroxaban demonstrated non-inferiority over enoxaparin/warfarin to prevent recurrent venous thromboembolism (VTE), with a reduction of major bleeding. However, compared to provoked VTE, the risk-benefit ratio of rivaroxaban may be different for patients with unprovoked VTE. METHODS: In a retrospective claims data analysis using US MarketScan claims from 1/2012 to 12/2016, we included adults with a primary diagnosis of VTE newly-initiated on rivaroxaban or warfarin within 30-days of the incident VTE and with ≥12-months of continuous insurance benefits prior to the VTE (baseline)...
May 30, 2018: Thrombosis Research
M J Moesker, N L Damen, E E Volmeijer, D Dreesens, E M de Loos, R Vink, M Coppens, M J Kruip, K Meijer, M Langelaan, M C de Bruijne, C Wagner
INTRODUCTION: Venous thromboembolism (VTE) prophylaxis guidelines for non-surgical patients recommend VTE- and bleeding risk assessment to guide prophylactic strategies. These recommendations differ between guidelines and implementation is suboptimal. Assessing a guideline's implementability characteristics helps predicting the ease of implementation and reveals barriers. OBJECTIVES: We aimed to compare guidelines' risk assessment recommendations and critically appraise the implementability characteristics...
May 26, 2018: Thrombosis Research
Isabella Garagiola, Roberta Palla, Flora Peyvandi
Although significant advances in hemophilia treatment have improved patient outcomes and quality of life, one of the greatest complications in severe hemophilia A is the development of anti-Factor VIII (FVIII) antibodies that inhibit FVIII activity in almost 30% of previously untreated patients (PUPs). Inhibitors make very difficult the management of patients and increase their morbidity and mortality reducing drastically their quality of life. Numerous studies have investigated the mechanisms leading to the development of FVIII inhibitors...
May 25, 2018: Thrombosis Research
Jeffrey A Kline, Angela M Ellison, Jessica Kanis, Jonathan W Pike, Cassandra L Hall
BACKGROUND: The pulmonary embolism rule out criteria (PERC) reliably predicts a low probability of PE in adults. We examine the diagnostic accuracy of the objective components of the PERC rule in children previously tested for PE. METHODS: Children aged 5-17 who had a D-dimer or pulmonary vascular imaging ordered from 2004 to 2014 in a large multicenter hospital network were identified by query of administrative databases. Using explicit, predefined methods, trained abstracters selected charts of children clearly tested for PE, collected the 8 objective variables for PERC, and determined PE criterion standard status (image or autopsy confirmed PE or deep vein thrombosis within 30 days by query of the Indiana Network for Patient Care (INPC))...
May 24, 2018: Thrombosis Research
Michael Feehan, Michael Walsh, Heather Van Duker, Jon Godin, Mark A Munger, Ryan Fleming, Stacy A Johnson, Margaux A Morrison, Margaret M DeAngelis, Daniel M Witt
INTRODUCTION: Venous thromboembolism (VTE) including deep vein thrombosis (DVT) or pulmonary embolism (PE) is associated with reduced survival, poorer quality of life, and substantial health-care-costs. Limited research, primarily qualitative, suggests that those with VTE may have elevated fear of recurrence, and associated emotional dysfunction and distress. METHODS: A national online survey was administered to 907 patients who had experienced a VTE event in the past two years...
May 23, 2018: Thrombosis Research
Carme Guerrero, Alberto Garay, Albert Ariza-Solé, Francesc Formiga, Sergio Raposeiras-Roubín, Emad Abu-Assi, Fabrizio D'Ascenzo, Timm Kinnaird, Sergio Manzano-Fernández, Oriol Alegre, José C Sánchez-Salado, Victòria Lorente, Christian Templin, Lazar Velicki, Ioanna Xanthopoulou, Enrico Cerrato, Andrea Rognoni, Giacomo Boccuzzi, Pierluigi Omedè, Andrea Montabone, Salma Taha, Alessandro Durante, Sebastiano Gili, Giulia Magnani, Federico Conrotto, Maurizio Bertaina, Michele Autelli, Alberto Grosso, Pedro Flores Blanco, Giorgio Quadri, Ferdinando Varbella, Francesco Tomassini, Berenice Caneiro Queija, Rafael Cobas Paz, María Cespón Fernández, Isabel Muñoz Pousa, Diego Gallo, Umberto Morbiducci, Alberto Dominguez-Rodriguez, Mariano Valdés, Dimitrios Alexopoulos, Andrés Iñiguez-Romo, Fiorenzo Gaita, Ángel Cequier
INTRODUCTION: Ticagrelor and prasugrel are recommended as first line therapy in patients with acute coronary syndromes (ACS). However, patients with anemia are commonly treated with clopidogrel in routine clinical practice. The RENAMI registry (REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction) included ACS patients treated with prasugrel or ticagrelor at hospital discharge. The aim of this study was to analyze the prevalence of anemia and characteristics and outcomes of these patients according to anemia status...
May 22, 2018: Thrombosis Research
Charlotte E A Dronkers, Willem M Lijfering, Martina Teichert, Felix J M van der Meer, Frederikus A Klok, Suzanne C Cannegieter, Menno V Huisman
BACKGROUND: Currently, direct oral anticoagulants (DOACs) are the treatment of choice for venous thromboembolism (VTE) in the Netherlands. The main advantages of DOACs over vitamin K antagonists (VKAs) are that they are safer than VKA and that neither monitoring nor dose titrations are needed. A main drawback is a potential risk of lower drug persistence, as compared with VKA treatment, which is strictly controlled by anticoagulation clinics in the Netherlands. OBJECTIVES: The primary aim of this study was to audit the persistence to DOAC treatment for acute VTE during the first 2 months in daily clinical practice...
May 19, 2018: Thrombosis Research
Anna Holm, Sofia Sederholm Lawesson, Shima Zolfagharian, Eva Swahn, Mattias Ekstedt, Joakim Alfredsson
INTRODUCTION: The aim of the current study was to assess bleeding events, including severity, localisation and prognostic impact, in a real world population of men and women with myocardial infarction (MI). METHODS AND RESULTS: In total 850 consecutive patients were included during 2010 and followed for one year. Bleeding complications were identified by searching of each patients' medical records and characterised according to the TIMI criteria. For this analysis, only the first event was calculated...
May 18, 2018: Thrombosis Research
L Traby, A Kaider, M Kollars, S Eichinger, M Wolzt, P A Kyrle
BACKGROUND: Dual-antiplatelet therapy (DAPT) is a standard strategy in acute coronary heart disease; however, it confers a considerable bleeding risk. Single-antiplatelet therapy (SAPT) inhibits haemostatic system activation ex vivo to a similar extent as DAPT. Extracellular vesicles (EV) are procoagulant and contribute to haemostatic system activation. We aimed to investigate the effect of DAPT compared with SAPT on EV. METHODS: In a randomized, double-blind, placebo-controlled trial, 44 healthy volunteers received DAPT (clopidogrel + aspirin) or SAPT (clopidogrel + placebo) for 7 days...
May 17, 2018: Thrombosis Research
Michael F Bode, Alyson C Auriemma, Steven P Grover, Yohei Hisada, Alex Rennie, Weeranun D Bode, Rashi Vora, Saravanan Subramaniam, Brian Cooley, Patricia Andrade-Gordon, Silvio Antoniak, Nigel Mackman
INTRODUCTION: Rivaroxaban selectively inhibits factor Xa (FXa), which plays a central role in blood coagulation. In addition, FXa activates protease-activated receptor-2 (PAR-2). We have shown that PAR-2-/- mice exhibit less cardiac dysfunction after cardiac injury. MATERIAL AND METHODS: Wild-type (WT) and PAR-2-/- mice were subjected to left anterior descending artery (LAD) ligation to induce cardiac injury and heart failure. Mice received either placebo or rivaroxaban chow either starting at the time of surgery or 3 days after surgery and continued up to 28 days...
May 17, 2018: Thrombosis Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"